TipRanks on MSN
Novo Nordisk expands cardiovascular ambitions with new phase 3 ziltivekimab plaque study
Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is running a Phase 3 trial called “Effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback